Why the study?
Does evolocumab reduce LDL cholesterol levels in pediatric patients with heterozygous familial hypercholesterolemia?
Does evolocumab reduce LDL cholesterol levels in pediatric patients with heterozygous familial hypercholesterolemia?
Evolocumab effectively reduces LDL cholesterol in pediatric patients with heterozygous familial hypercholesterolemia.
Answers are grounded in this paper and cite their sources.
Supports LDL management in pediatric HeFH; extends adult RCT data to this population.
In this trial involving pediatric patients with familial hypercholesterolemia, evolocumab reduced the LDL cholesterol level and other lipid variables. (Funded by Amgen; HAUSER-RCT ClinicalTrials.gov number, NCT02392559.).
No takes yet. Share an insight, caveat, or question.
Santos et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: